Sensitivity analyses Compared with SGLT2i alone, combination therapy in people 65 years of age was significantly associated with 51%, 33%, 46%, and 45% lower risk of ischemic stroke, MI, 3-point MACE, and 5-point MACE, respectively (See Supplementary Table 6, Supplementary Materials)
What insurance typically covers FDA-approved peptides for approved indications: Semaglutide (Ozempic) for type 2 diabetes: Often covered Semaglutide (Wegovy) for obesity: Sometimes covered with restrictions Tirzepatide (Mounjaro) for type 2 diabetes: Often covered Tirzepatide (Zepbound) for obesity: Limited coverage What coverage looks like: Prior authorization typically required Documentation of failed dietary interventions BMI thresholds for weight loss indications Co-pays still substantial ($100-500 monthly) What insurance doesn't cover The vast majority of peptide therapy falls outside insurance coverage: Compounded peptides (BPC-157, TB-500, most growth hormone peptides) Anti-aging applications even for FDA-approved drugs Performance enhancement uses Off-label applications These costs are entirely out-of-pocket for most patients
"Mechanisms" people cite (and what they don't prove) You'll often see references to growth factors and vascular signaling (like pathways associated with tissue repair)
conducted experiments on kidney cells and found that mechanotransduction is not a mere on/off switch for apoptosis [137]
